Evidence map›Paper›PMID 39682152›Full record

ReviewCancers2024

Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.

Valentina Ramírez Maldonado, Josgrey Navas Acosta, Iván Maldonado Marcos, Ángela Villaverde Ramiro, Alberto Hernández-Sánchez, Jesús M Hernández Rivas, Rocío Benito Sánchez

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Genes · 2026
    Article
  2. [Recent advances in individualized treatment for pediatric high-risk B-cell acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valentina Ramírez MaldonadoCentro de Investigación del Cáncer, IBMCC, CSIC, Universidad de Salamanca, IBSAL (Instituto de Investigación Biomédica de Salamanca) Campus, Miguel de Unamuno, 37007 Salamanca, Spain.
Josgrey Navas AcostaCentro de Investigación del Cáncer, IBMCC, CSIC, Universidad de Salamanca, IBSAL (Instituto de Investigación Biomédica de Salamanca) Campus, Miguel de Unamuno, 37007 Salamanca, Spain.
Iván Maldonado MarcosCentro de Investigación del Cáncer, IBMCC, CSIC, Universidad de Salamanca, IBSAL (Instituto de Investigación Biomédica de Salamanca) Campus, Miguel de Unamuno, 37007 Salamanca, Spain.ORCID 0000-0001-5550-2524
Ángela Villaverde RamiroCentro de Investigación del Cáncer, IBMCC, CSIC, Universidad de Salamanca, IBSAL (Instituto de Investigación Biomédica de Salamanca) Campus, Miguel de Unamuno, 37007 Salamanca, Spain.ORCID 0000-0002-7337-7218
Alberto Hernández-SánchezCentro de Investigación del Cáncer, IBMCC, CSIC, Universidad de Salamanca, IBSAL (Instituto de Investigación Biomédica de Salamanca) Campus, Miguel de Unamuno, 37007 Salamanca, Spain.ORCID 0000-0002-6601-3096
Jesús M Hernández RivasCentro de Investigación del Cáncer, IBMCC, CSIC, Universidad de Salamanca, IBSAL (Instituto de Investigación Biomédica de Salamanca) Campus, Miguel de Unamuno, 37007 Salamanca, Spain.ORCID 0000-0002-9661-9371
Rocío Benito SánchezCentro de Investigación del Cáncer, IBMCC, CSIC, Universidad de Salamanca, IBSAL (Instituto de Investigación Biomédica de Salamanca) Campus, Miguel de Unamuno, 37007 Salamanca, Spain.ORCID 0000-0001-9781-4198

Funding

Consejería de Educación, Junta Castilla y León, Co-funded by the European Regional Development Fund (FEDER), SA198P24Fundación Mutua Madrileña FMM21/002 AP176752021Proyectos de Investigación del SACYL, Spain, Gerencia Regional de Salud de Castilla y León GRS2823/A1/2023
6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is a hematological neoplasm characterized by the clonal expansion of abnormal lymphoid precursors in bone marrow, which leads to alterations in the processes of cell differentiation and maturation as a consequence of genetic alterations. The integration of conventional methods, such as cytogenetics and immunophenotyping, and next-generation sequencing (NGS) has led to significant improvements at diagnosis and patient stratification; this has also allowed the discovery of several novel molecular entities with specific genetic variants that may drive the processes of leukemogenesis. Nevertheless, the understanding of the process of leukemogenesis remains a challenge since this disease persists as the most frequent cancer in children; it accounts for approximately one-quarter of adult acute leukemias, and the patient management may take into consideration the high intra- and inter-tumor heterogeneity and the relapse risk due to the various molecular events that can occur during clonal evolution. Some germline variants have been identified as risk factors or have been found to be related to the response to treatment. Therefore, better knowledge of the genetic alterations in B-ALL will have a prognostic impact from the perspective of personalized medicine. This review aims to compare, synthesize, and highlight recent findings concerning ALL obtained through NGS that have led to a better understanding of new molecular subtypes based on immunophenotypic characteristics, mutational profiles, and expression profiles.

Indexed as

acute lymphoblastic leukemianext-generation sequencing (NGS)personalized medicinewhole-genome sequencing

Identifiers

PMID39682152
PMCPMC11639785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.